Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 6, pp. 749-759
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 17
Interleukin-17: A Pleiotropic Cytokine Implicated in Inflammatory, Infectious, and Malignant Disorders
Anna Saran, Daisuke Nishizaki, Scott M. Lippman, et al.
Cytokine & Growth Factor Reviews (2025)
Open Access | Times Cited: 3
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 4, pp. 477-485
Open Access | Times Cited: 18
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Joshua Burshtein, Milaan Shah, Danny Zakria, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 2, pp. 323-339
Open Access | Times Cited: 5
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 10, pp. 2841-2857
Open Access | Times Cited: 5
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Andrew Blauvelt, April W. Armstrong, Joseph F. Merola, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 1, pp. 72-81
Open Access | Times Cited: 4
Long‐term maintenance of responses to bimekizumab treatment in moderate‐to‐severe psoriasis: A real‐world comparison of Q4W versus Q8W dosing or bio‐naïve versus bio‐switched patients
Marina Onda, Teppei Hagino, Hidehisa Saeki, et al.
The Journal of Dermatology (2025)
Open Access
Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector
Michael Sebastian, Jerry Bagel, Bengt Hoepken, et al.
Dermatology and Therapy (2025)
Open Access
Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy
Annunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
Dermatology Practical & Conceptual (2025) Vol. 15, pp. 4976-4976
Open Access
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission
David Ranzinger, Kilian Eyerich
American Journal of Clinical Dermatology (2025)
Open Access
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Matteo Megna, Chiara Assorgi, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Effectiveness of long‐term bimekizumab treatment and predictive factors for responders in moderate‐to‐severe psoriasis: A 52‐week real‐world study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2024)
Closed Access | Times Cited: 3
Bimekizumab for the treatment of hidradenitis suppurativa
Rayad B. Shams, Christopher Sayed
Immunotherapy (2024), pp. 1-9
Closed Access | Times Cited: 2
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Mark Lebwohl, Joseph F. Merola, Bruce Strober, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 281-289
Open Access | Times Cited: 1
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 12, pp. 3291-3306
Open Access | Times Cited: 1
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
Gemma Camiña‐Conforto, Laura Mateu Arrom, A. López‐Ferrer, et al.
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 1541-1549
Open Access | Times Cited: 3
Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report
Danny Zakria, Lauren E. Miller, T Y Chao, et al.
SKIN The Journal of Cutaneous Medicine (2024) Vol. 8, Iss. 2, pp. 1348-1364
Open Access
Bimekizumab for The Treatment of Psoriasis
Molly Thapar, Milan Patel, Kenneth B. Gordon
Immunotherapy (2024) Vol. 16, Iss. 7, pp. 431-446
Closed Access
Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.
Jacob Beer, Sarah Hermak, Omar Noor
PubMed (2024) Vol. 17, Iss. 5 Suppl 2, pp. S7-S10
Closed Access
What Is New in Nail Psoriasis?
Dimitris Rigopoulos, Aikaterini Tsiogka, Dimitrios Malanos, et al.
Skin Appendage Disorders (2024), pp. 1-13
Closed Access
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
L. Puig, Antonio Costanzo, E.M.G.J. de Jong, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2539-2558
Open Access
Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study
Sang Woong Youn, Seong Jin Jo, Chul Jong Park, et al.
The Journal of Dermatology (2024)
Open Access
Mechanistic Understanding of Clinical Response to Bimekizumab in Psoriatic Disease
Eleanor Roberts
EMJ Dermatology (2024), pp. 50-57
Open Access
Bimekizumab: A novel FDA approved dual IL-17 A/F inhibitor for moderate to severe psoriasis
Febin Ashraf, Simin Muhammed Kutty
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-5
Open Access
Safety and longevity of biological treatment in the setting of moderate-to-severe psoriasis: enhancing the body of evidence
Lynda Spelman
British Journal of Dermatology (2023) Vol. 188, Iss. 6, pp. 696-696
Closed Access
Page 1 - Next Page

Scroll to top